BCYC

BICYCLE THERAPEUTICS PLC BCYC

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,917 of 2,925

Why it scores 5Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$629.0K

Quarter to Jun 30

Net income

$-50.33M

Quarter to Jun 30

Free cash flow

$-49.87M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$158.03M total
BAKER BROS. ADVISORS LP
$46.15M0.0%
FCPM III SERVICES B.V.
$14.71M0.0%
ARMISTICE CAPITAL, LLC
$14.41M0.0%
Long Focus Capital Management, LLC
$14.04M0.0%
ACADIAN ASSET MANAGEMENT LLC
$8.32M0.0%
RENAISSANCE TECHNOLOGIES LLC
$6.50M+56.6%
GSK plc
$6.49M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$3.83M-12.3%
MARSHALL WACE, LLP
$3.38M+111.5%
Qube Research & Technologies Ltd
$3.29M+151.3%
MORGAN STANLEY
$2.83M+7.9%
SCHRODER INVESTMENT MANAGEMENT GROUP
$2.56M0.0%
CITADEL ADVISORS LLC
$2.35M+47.0%
MILLENNIUM MANAGEMENT LLC
$2.35M+95.1%
Peapod Lane Capital LLC
$2.28M+344.2%
DIADEMA PARTNERS LP
$1.96M-2.9%
TWO SIGMA INVESTMENTS, LP
$1.84M+163.7%
JANE STREET GROUP, LLC
$1.66M+79.8%
Birchview Capital, LP
$1.33M-32.4%
BlackRock, Inc.
$1.19M+0.5%
MOORE CAPITAL MANAGEMENT, LP
$1.17M0.0%
Rangeley Capital, LLC
$1.07M+9.1%
FLAX POND CAPITAL, LLC
$910.1K+11.4%
Palo Alto Investors LP
$856.0K0.0%
Sculptor Capital LP
$839.1KNew
See all 104 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BCYC

Earnings Per Share

13fpro.ai/company/BCYC

Loading ratio trend…

BCYC key financials by period

Reported revenue, net income and operating margin by fiscal year, from BICYCLE THERAPEUTICS PLC's annual filings on SEC EDGAR.

BICYCLE THERAPEUTICS PLC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$72.6M$-219.0M—
FY 2024$35.3M$-169.0M—
FY 2023$27.0M$-180.7M—
FY 2022$14.5M$-112.7M—
FY 2021$11.7M$-66.8M—
FY 2020$10.4M$-51.0M—
Source: BCYC filings on SEC EDGAR →

Companies similar to BCYC

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

BCYC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BICYCLE THERAPEUTICS PLC (BCYC): stock profile, AI score and financials

BICYCLE THERAPEUTICS PLC (BCYC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCYC at 5.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,917 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BICYCLE THERAPEUTICS PLC reports quarterly revenue of $629.0K, net income of $-50.3M, free cash flow of $-49.9M. Top institutional holders of BCYC by reported 13-F value include BAKER BROS. ADVISORS, FCPM III SERVICES B.V., ARMISTICE CAPITAL, based on the most recent SEC filings. BCYC trades on the Nasdaq exchange and files with the SEC under CIK 1761612. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCYC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BICYCLE THERAPEUTICS PLC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1761612 →